TASCENSO ODT

Product NDC: 70709-065
11-digit product format: 707090065
Labeler code: 70709
Product ID: 70709-065_eb717a3b-e703-4637-83c7-fccdecbac199
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: Fingolimod Lauryl Sulfate
Dosage form: TABLET, ORALLY DISINTEGRATING
Route: ORAL
Labeler: Cycle Pharmaceuticals Ltd
Application: NDA214962
Marketing category: NDA
Marketing start: 2023-02-01
Substance: FINGOLIMOD LAURYL SULFATE
Active strength: .5 mg/1
Pharmacologic classes: Sphingosine 1-Phosphate Receptor Modulators [MoA], Sphingosine 1-phosphate Receptor Modulator [EPC]
NDC exclude flag: No
Listing certified through: 2027-12-31
Current FDA listing: Yes

Source provenance: Browse the complete Orange Book source catalog · source snapshot 1.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	TE codes	RLD / RS	Approval date
N214962-001	TASCENSO ODT	FINGOLIMOD LAURYL SULFATE	EQ 0.25MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL		RLD	2021-12-23
N214962-002	TASCENSO ODT	FINGOLIMOD LAURYL SULFATE	EQ 0.5MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL		RLD, RS	2022-12-09

Orange Book patents#

Current patent rows page 1 of 1 · 6 matching rows.

Application-product, Patent, Expiration table
Application-product	Patent	Expiration	Use code	Coverage / status	Submission date
N214962-001	10555902	2036-01-19	U-3268		2022-01-11
N214962-001	10925829	2036-01-19		Drug product	2022-01-11
N214962-001	9925138	2036-01-19		Drug product	2022-01-11
N214962-002	10555902	2036-01-19	U-3493		2022-12-16
N214962-002	10925829	2036-01-19		Drug product	2022-12-16
N214962-002	9925138	2036-01-19		Drug product	2022-12-16

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 56 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	RLD / RS	Approval date	Source SHA-256
2026-02-19 14:30 UTC	2026-02	N214962-001	TASCENSO ODT	EQ 0.25MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD	2021-12-23	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N214962-002	TASCENSO ODT	EQ 0.5MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD, RS	2022-12-09	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N214962-001	TASCENSO ODT	EQ 0.25MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD	2021-12-23	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N214962-002	TASCENSO ODT	EQ 0.5MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD, RS	2022-12-09	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N214962-001	TASCENSO ODT	EQ 0.25MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD	2021-12-23	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N214962-002	TASCENSO ODT	EQ 0.5MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD, RS	2022-12-09	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N214962-001	TASCENSO ODT	EQ 0.25MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD	2021-12-23	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N214962-002	TASCENSO ODT	EQ 0.5MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD, RS	2022-12-09	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N214962-001	TASCENSO ODT	EQ 0.25MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD	2021-12-23	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N214962-002	TASCENSO ODT	EQ 0.5MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD, RS	2022-12-09	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N214962-001	TASCENSO ODT	EQ 0.25MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD	2021-12-23	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N214962-002	TASCENSO ODT	EQ 0.5MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD, RS	2022-12-09	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N214962-001	TASCENSO ODT	EQ 0.25MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD	2021-12-23	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N214962-002	TASCENSO ODT	EQ 0.5MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD, RS	2022-12-09	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N214962-001	TASCENSO ODT	EQ 0.25MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD	2021-12-23	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N214962-002	TASCENSO ODT	EQ 0.5MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD, RS	2022-12-09	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N214962-001	TASCENSO ODT	EQ 0.25MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD	2021-12-23	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N214962-002	TASCENSO ODT	EQ 0.5MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD, RS	2022-12-09	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	N214962-001	TASCENSO ODT	EQ 0.25MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD	2021-12-23	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N214962-002	TASCENSO ODT	EQ 0.5MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD, RS	2022-12-09	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N214962-001	TASCENSO ODT	EQ 0.25MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD	2021-12-23	`79d66fd596c7…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N214962-002	TASCENSO ODT	EQ 0.5MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD, RS	2022-12-09	`79d66fd596c7…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N214962-001	TASCENSO ODT	EQ 0.25MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD	2021-12-23	`301d65b070ca…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N214962-002	TASCENSO ODT	EQ 0.5MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD, RS	2022-12-09	`301d65b070ca…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N214962-001	TASCENSO ODT	EQ 0.25MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD	2021-12-23	`1e350fbaab3a…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N214962-002	TASCENSO ODT	EQ 0.5MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD, RS	2022-12-09	`1e350fbaab3a…`
2024-05-31 18:47 UTC	2024-05	N214962-001	TASCENSO ODT	EQ 0.25MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD	2021-12-23	`8072bd15b7f6…`
2024-05-31 18:47 UTC	2024-05	N214962-002	TASCENSO ODT	EQ 0.5MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD, RS	2022-12-09	`8072bd15b7f6…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N214962-001	TASCENSO ODT	EQ 0.25MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD, RS	2021-12-23	`5c6f7cd8ea54…`
2022-04-08 23:34 UTC	2022-04	N214962-001	TASCENSO ODT	EQ 0.25MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD, RS	2021-12-23	`5d02ea3f76ae…`
2022-04-04 05:41 UTC	2022-04	N214962-001	TASCENSO ODT	EQ 0.25MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD, RS	2021-12-23	`4b0b4de00fa7…`
2022-03-09 01:35 UTC	2022-03	N214962-001	TASCENSO ODT	EQ 0.25MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD, RS	2021-12-23	`bb7c543d1eb4…`
2024-03-16 18:09 UTC · 4 captures of this ZIP	2024-03	N214962-001	TASCENSO ODT	EQ 0.25MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD	2021-12-23	`6a51e52b5d6a…`
2024-03-16 18:09 UTC · 4 captures of this ZIP	2024-03	N214962-002	TASCENSO ODT	EQ 0.5MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD, RS	2022-12-09	`6a51e52b5d6a…`
2024-02-18 07:12 UTC	2024-02	N214962-001	TASCENSO ODT	EQ 0.25MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD	2021-12-23	`1c564ffb4f44…`
2024-02-18 07:12 UTC	2024-02	N214962-002	TASCENSO ODT	EQ 0.5MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD, RS	2022-12-09	`1c564ffb4f44…`
2023-12-20 04:57 UTC	2023-12	N214962-001	TASCENSO ODT	EQ 0.25MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD	2021-12-23	`ea1830bbd6c7…`
2023-12-20 04:57 UTC	2023-12	N214962-002	TASCENSO ODT	EQ 0.5MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD, RS	2022-12-09	`ea1830bbd6c7…`
2023-11-28 05:40 UTC · 2 captures of this ZIP	2023-11	N214962-001	TASCENSO ODT	EQ 0.25MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD	2021-12-23	`a72a2bbeb626…`
2023-11-28 05:40 UTC · 2 captures of this ZIP	2023-11	N214962-002	TASCENSO ODT	EQ 0.5MG BASE	TABLET, ORALLY DISINTEGRATING / ORAL	RLD, RS	2022-12-09	`a72a2bbeb626…`

Observed Orange Book patent history#

Patent history page 1 of 5 · 168 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Patent	Expiration	Use code	Coverage / status	Submission date	Source SHA-256
2026-02-19 14:30 UTC	2026-02	N214962-001	10555902	2036-01-19	U-3268		2022-01-11	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N214962-001	10925829	2036-01-19		Drug product	2022-01-11	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N214962-001	9925138	2036-01-19		Drug product	2022-01-11	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N214962-002	10555902	2036-01-19	U-3493		2022-12-16	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N214962-002	10925829	2036-01-19		Drug product	2022-12-16	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N214962-002	9925138	2036-01-19		Drug product	2022-12-16	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N214962-001	10555902	2036-01-19	U-3268		2022-01-11	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N214962-001	10925829	2036-01-19		Drug product	2022-01-11	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N214962-001	9925138	2036-01-19		Drug product	2022-01-11	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N214962-002	10555902	2036-01-19	U-3493		2022-12-16	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N214962-002	10925829	2036-01-19		Drug product	2022-12-16	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N214962-002	9925138	2036-01-19		Drug product	2022-12-16	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N214962-001	10555902	2036-01-19	U-3268		2022-01-11	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N214962-001	10925829	2036-01-19		Drug product	2022-01-11	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N214962-001	9925138	2036-01-19		Drug product	2022-01-11	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N214962-002	10555902	2036-01-19	U-3493		2022-12-16	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N214962-002	10925829	2036-01-19		Drug product	2022-12-16	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N214962-002	9925138	2036-01-19		Drug product	2022-12-16	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N214962-001	10555902	2036-01-19	U-3268		2022-01-11	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N214962-001	10925829	2036-01-19		Drug product	2022-01-11	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N214962-001	9925138	2036-01-19		Drug product	2022-01-11	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N214962-002	10555902	2036-01-19	U-3493		2022-12-16	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N214962-002	10925829	2036-01-19		Drug product	2022-12-16	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N214962-002	9925138	2036-01-19		Drug product	2022-12-16	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N214962-001	10555902	2036-01-19	U-3268		2022-01-11	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N214962-001	10925829	2036-01-19		Drug product	2022-01-11	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N214962-001	9925138	2036-01-19		Drug product	2022-01-11	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N214962-002	10555902	2036-01-19	U-3493		2022-12-16	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N214962-002	10925829	2036-01-19		Drug product	2022-12-16	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N214962-002	9925138	2036-01-19		Drug product	2022-12-16	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N214962-001	10555902	2036-01-19	U-3268		2022-01-11	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N214962-001	10925829	2036-01-19		Drug product	2022-01-11	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N214962-001	9925138	2036-01-19		Drug product	2022-01-11	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N214962-002	10555902	2036-01-19	U-3493		2022-12-16	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N214962-002	10925829	2036-01-19		Drug product	2022-12-16	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N214962-002	9925138	2036-01-19		Drug product	2022-12-16	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N214962-001	10555902	2036-01-19	U-3268		2022-01-11	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N214962-001	10925829	2036-01-19		Drug product	2022-01-11	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N214962-001	9925138	2036-01-19		Drug product	2022-01-11	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N214962-002	10555902	2036-01-19	U-3493		2022-12-16	`2680178bc6a6…`

Additional Listing Data#

Finished product: Yes
Brand name base: TASCENSO ODT
Listing expiration: 2027-12-31

Active Ingredients#

Ingredient, Strength table
Ingredient	Strength
FINGOLIMOD LAURYL SULFATE	.5 mg/1

Harmonized UNII identifiers#

UNII identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
Identifier	FDA.report destination
J3HZQ9BE2S	Internal UNII lookup

Harmonized RxCUI identifiers#

RxCUI identifiers page 1 of 1 · 4 matching rows.

Identifier, FDA.report destination table
Identifier	FDA.report destination
2610295	Internal RxNorm lookup
2610302	Internal RxNorm lookup
2626383	Internal RxNorm lookup
2626385	Internal RxNorm lookup

Harmonized SPL set identifiers#

SPL set identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
Identifier	FDA.report destination
bf8e7f89-ea09-43c7-a7eb-e44724350721	Available on FDA.report

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
665f4aef-df96-42b3-97d1-5971737de3dc	Product name	9	20250121
6b6bc7ea-a5a8-4e5e-b81d-4b6b4cbe6f45	Product name	1	20230919

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	Strength	SPL version
70709-065-30	TASCENSO ODT	3 in 1 CARTON	TABLET, ORALLY DISINTEGRATING	3		8
70709-065-30	TASCENSO ODT	10 in 1 BLISTER PACK	TABLET, ORALLY DISINTEGRATING	10		8

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
70709-065-30	EA - Each	70709-065	2e29e457-54eb-49bf-ae5e-51f546400fe6	1	2023-02-06

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
70709-065	TASCENSO ODT (FINGOLIMOD LAURYL SULFATE) TABLET, ORALLY DISINTEGRATING [CYCLE PHARMACEUTICALS LTD]	7	Current NDC, 2 package rows	20250327_bf8e7f89-ea09-43c7-a7eb-e44724350721.zip

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
TASCENSO ODT	FINGOLIMOD LAURYL SULFATE	Cycle Pharmaceuticals Ltd	bf8e7f89-ea09-43c7-a7eb-e44724350721	2026-01-08	Warnings, Adverse reactions	Exact identifier application applno (NDA): 214962 application number: NDA214962 ndc (product): 70709-065

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	DailyMed	SPL version
2610295	fingolimod 0.25 MG Disintegrating Oral Tablet	PSN	bf8e7f89-ea09-43c7-a7eb-e44724350721	8
2626383	fingolimod 0.5 MG Disintegrating Oral Tablet	PSN	bf8e7f89-ea09-43c7-a7eb-e44724350721	8
2610302	Tascenso ODT 0.25 MG Disintegrating Oral Tablet	PSN	bf8e7f89-ea09-43c7-a7eb-e44724350721	8
2626385	Tascenso ODT 0.5 MG Disintegrating Oral Tablet	PSN	bf8e7f89-ea09-43c7-a7eb-e44724350721	8
2610302	fingolimod 0.25 MG Disintegrating Oral Tablet [Tascenso]	SBD	bf8e7f89-ea09-43c7-a7eb-e44724350721	8
2626385	fingolimod 0.5 MG Disintegrating Oral Tablet [Tascenso]	SBD	bf8e7f89-ea09-43c7-a7eb-e44724350721	8
2610295	fingolimod 0.25 MG Disintegrating Oral Tablet	SCD	bf8e7f89-ea09-43c7-a7eb-e44724350721	8
2626383	fingolimod 0.5 MG Disintegrating Oral Tablet	SCD	bf8e7f89-ea09-43c7-a7eb-e44724350721	8
2610295	fingolimod 0.25 MG (as fingolimod lauryl sulfate 0.47 MG) Disintegrating Oral Tablet	SY	bf8e7f89-ea09-43c7-a7eb-e44724350721	8
2610302	Tascenso 0.25 MG (as fingolimod lauryl sulfate 0.47 MG) Disintegrating Oral Tablet	SY	bf8e7f89-ea09-43c7-a7eb-e44724350721	8
2626385	Tascenso 0.5 MG Disintegrating Oral Tablet	SY	bf8e7f89-ea09-43c7-a7eb-e44724350721	8

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Units	Marketing start	Sample	Exclude flag	Status
70709-065-30	70709006530	3 BLISTER PACK in 1 CARTON (70709-065-30) / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK	3 blister pack	2023-02-01	No	No	Current

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
TASCENSO ODT	Cycle Pharmaceuticals Ltd \| Catalent U.K. Swindon Zydis Limited	2026-01-08	HUMAN PRESCRIPTION DRUG LABEL	8